Solid Tumors
Conditions
Keywords
EGFR exon 20 insertion mutation, Atypical EGFR mutation, HER2 exon 20 insertion mutation, HER2 amplification/overexpression, NSCLC, Breast cancer
Brief summary
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.
Detailed description
ORIC-114 is a brain penetrant, selective, orally bioavailable, irreversible small molecule inhibitor designed to target EGFR and HER2 alterations, making it a promising therapeutic candidate for development in patients whose tumors harbor these alterations, including those with CNS metastases. This is a first-in-human, open-label, single arm, multicenter, dose escalation study of ORIC-114 as a single agent (Part I), followed by dose optimization (Part II) to establish the recommended phase 2 dose (RP2D) and antitumor activity of ORIC-114 in patients with advanced solid tumors harboring an EGFR or HER2 alteration who have exhausted available treatment options. After the optimal RP2D has been determined, Phase 2 will be initiated via protocol amendment to add one or more expansion cohorts of patients with specific tumor types, treatment history, and/or expression of a specific biomarker to evaluate the antitumor activity of ORIC-114. After completion of Part I dose escalation, Part III, a dose escalation study of ORIC-114 in combination with chemotherapy (carboplatin-pemetrexed) may be initiated to establish the RP2D and/or MTD and antitumor activity for the combination (US sites only).
Interventions
DRUGORIC-114
ORIC-114 oral daily
DRUGChemotherapy drug
21 days for up to 4 cycles
Sponsors
ORIC Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Interval 3+3 dose escalation design
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation or atypical EGFR mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/overexpression as determined by an immunohistochemistry (IHC) or an in situ hybridization (ISH) test 1. Part I Dose Escalation (CLOSED) Any solid tumor with * EGFR exon 20 insertion mutation * HER2 exon 20 insertion mutation * Atypical EGFR mutations (NSCLC only) (Appendix 8) * HER2 amplification or overexpression (HER2+) * Previously received and progressed on or after available standard therapies and for whom additional standard therapy is considered unsuitable or intolerable 2. Part I Extension (ONGOING) * Cohort IA: Patients with HER2+ breast cancer previously received and progressed on or after available standard therapies and for whom additional standard therapy is considered unsuitable or intolerable * Cohort IB: NSCLC patients with EGFR exon 20 insertion mutation previously treated with chemotherapy and amivantamab * Cohort IC: Treatment-naïve NSCLC patients with EGFR exon 20 insertion mutation * Cohort ID: Treatment-naïve NSCLC patients with EGFR atypical mutations 3. Part II Dose Optimization (ONGOING): NSCLC patients with * Cohort IIA: EGFR exon 20 insertion mutation, patients must have received platinum-based chemotherapy or other chemotherapy regimen if platinum- based chemotherapy was contraindicated. Additionally, patients must be naïve to an EGFR exon 20 targeted agent, ie, must have declined or be ineligible for all available exon 20 targeted therapies with proven benefit * Cohort IIB: HER2 exon 20 insertion mutation, patients must have received platinum-based chemotherapy or other chemotherapy regimen if platinum- based chemotherapy was contraindicated. Additionally, patients must be naïve to a HER2 exon 20 targeted TKI * Cohort IIC: Atypical EGFR mutation, patients may have received a prior EGFR TKI * Agreement and ability to undergo pretreatment biopsy * Measurable disease according to RECIST 1.1 * CNS involvement, which is either previously treated and controlled, or untreated and asymptomatic * ECOG performance status of 0 or 1 * Adequate organ function
Exclusion criteria
* Known EGFR T790M mutation * Leptomeningeal disease and spinal cord compression \-- Except if LMD has been reported radiographically on baseline MRI, but is not suspected clinically by the Investigator; the subject must be free of neurological symptoms of LMD * History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months * Past medical history of interstitial lung disease (ILD), drug induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD * Known, symptomatic human immunodeficiency virus (HIV) infection * Known active infection requiring treatment or history of hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients positive for HBsAg but normal HBV DNA level are allowed. * Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes * Any other concurrent serious uncontrolled medical, psychological, or addictive conditions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum plasma concentration (Cmax) | 28 Days | PK of ORIC-114 |
| Time of maximum observed concentration (Tmax) | 28 Days | PK of ORIC-114 |
| Area under the curve (AUC) | 28 Days | PK of ORIC-114 |
| Apparent plasma terminal elimination half-life (t1/2) | 28 Days | PK of ORIC-114 |
| Recommended Phase 2 Dose (RP2D) | 12 months | RP2D as determined by interval 3+3 dose escalation design |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intracranial progression-free survival (PFS) | 36 months | Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 |
| Objective response rate (ORR) | 36 months | Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 |
| Duration of response (DOR) | 36 months | Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 |
| Clinical benefit rate (CBR) | 36 months | Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 |
| Progression-free survival (PFS) | 36 months | Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 |
| Intracranial response rate (CR and/or PR) | 36 months | Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 |
Countries
Australia, Canada, Hong Kong, Malaysia, Poland, South Korea, Spain, Taiwan, United Kingdom, United States
Contacts
CONTACTORIC Clinical
STUDY_DIRECTORPratik S. Multani, MD, MS
ORIC Pharmaceuticals
Outcome results
None listed